1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Global Pharmaceutical Analysis & Statistics

Global Pharmaceutical Analysis & Statistics

Customer Support

Talk to Ahmad

+1 718 618 4302

Publication dates

Publishers

  • All
    • Bioseeker

All regions

1-12 of 12 reports

Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool

  • $ 1450
  • May 2019
  • 1 pages

Targeting the CD47-SIRP? axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune response. This report reveals intense global interest and a growing ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Bispecific CD3 Molecules in Oncology: Analytical Tool

  • $ 1950
  • December 2018
  • 1 pages

There is a considerable and robust commercial drug pipeline of T-cell redirecting therapies by bispecific compounds that targets various tumor antigens expressed by malignant cells, and CD3 expressed by ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Immuno-Oncology Drug Development: Analytical Tool

  • $ 4450
  • December 2018
  • 1 pages

Immuno-Oncology (I-O) has quickly become to be the 4th pillar of cancer therapy and encompasses a highly diverse portfolio of treatment strategies from the early interferon-?/interleukin-2 therapies to ...

  • Drug Development
  • Pharmaceutical
  • Therapy
  • World

CAR/TCR Therapies in Oncology: Analytical Tool

  • $ 2950
  • December 2018
  • 1 pages

Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) therapies are a game changer within cancer therapies and there is a place in history and huge recognition to both Novartis and Kite Pharma (now ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Protein Kinase Inhibitors in Oncology: Analytical Tool

  • $ 4450
  • December 2018
  • 1 pages

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Oncolytic Virotherapies: Analytical Tool

  • $ 1950
  • December 2018
  • 1 pages

Oncolytic virotherapy is a hot emerging treatment modality were therapeutically useful anticancer viruses will selectively infect and damage cancerous tissues without causing harm to normal tissues. Oncolytic ...

  • Animal Therapy
  • Pharmaceutical
  • Therapy
  • World

Immune-checkpoint Drugs in Oncology: Analytical Tool

  • $ 2950
  • December 2018
  • 1 pages

Cancer cells sometimes find ways to avoid being attacked by the immune system. But the event of immune-checkpoint drugs such as nivolumab (Opdivo) and pembrolizumab (Keytruda) have dramatically changed ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Conjugated Antibodies in Oncology: Analytical Tool

  • $ 3950
  • December 2018
  • 1 pages

The first Antibody-Drug Conjugate (ADC) to receive marketing approval from the US Food and Drug Administration (FDA) was gemtuzumab ozogamicin (Mylotarg) in 2000 which represents a powerful, emerging novel ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

RNA Therapies in Oncology: Analytical Tool

  • $ 2950
  • December 2018
  • 1 pages

RNA therapies, such as miRNA, RNAi & siRNA, is an emerging class of biopharmaceutical that has immense potential in cancer medicine. Critical to the field, recent developments in delivery technologies ...

  • Oncology
  • Pharmaceutical
  • RNA
  • Therapy
  • World

Cancer Vaccines: Analytical Tool

  • $ 3950
  • December 2018
  • 1 pages

With the first prophylactic cancer vaccine Gardasil approved in 2006 and therapeutic cancer vaccine Sipuleucel-T (Provenge) approved in 2010, cancer vaccines is a proven hot treatment modality which is ...

  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Bispecific Molecules in Oncology: Analytical Tool

  • $ 2950
  • December 2018
  • 1 pages

Bispecific molecules carry huge treatment potential within cancer immunotherapy. In broad strokes this therapeutic category can be divided into three classes: (I) cytotoxic effector cell redirectors/CTL ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • World
  • Market Description

Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool

  • $ 1450
  • October 2018
  • 1 pages

The Commercial Interest at ESMO Annual Meeting 2018: Analytical Tool is a must have companion tool for reviewing the direction of commercial drug development emerging from the European Society of Medical ...

  • Oncology
  • Pharmaceutical
  • Therapy
  • Europe
  • World



Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on